The Effect of ADT on PSMA Expression in Metastatic Prostate Cancer

• Status: Recruiting
• Trial end date: 2023-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

Thirty-five men with newly diagnosed, metastatic prostate cancer are scanned with 18F-PSMA 1007 PET/CT at baseline, 3 weeks after the initiation of GnRH-antagonist, at one year and at the time of castration resistant prostate cancer (CRPC). The aim of the study is to classify metastatic lesions into those with PSMA-flare and those without and determine their potential to progress during the follow-up until CRPC.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Turku University Hospital

Criteria

Inclusion Criteria:

• Age: 40 to 85 years old

• Language spoken: Finnish

• Diagnosis: Histologically confirmed adenocarcinoma of prostate

• Adequate histological sampling consisting of at least 3 biopsy samples from each lobe

• No previous surgical, radiation or endocrine treatment for prostate carcinoma

• Clinical stage:T1c-T4NanyM1

• Serum creatinine ≤ 1,5 x ULN

• Mental status: Patients must be able to understand the meaning of the study

• Informed consent: The patient must sign the appropriate Ethical Committee approved informed consent documents in the presence of the designated staff

Exclusion Criteria:

• Previous PC treatment

• Uncontrolled serious infection

• Prior usage of 5-ARI medication in past 12 months